Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Association Between Interleukin-18 Level and Left Ventricular Mass Index in Hypertensive Patients

  • Received : 2016.10.03
  • Accepted : 2016.11.01
  • Published : 2017.03.31
⟨ Previous Next ⟩

Abstract

Background and Objectives: In clinical trials, hypertensive patients tend to have higher interleukin-18 (IL-18) concentrations than normotensive groups, but the relationship between IL-18 and left ventricular hypertrophy (LVH), which is a marker of end-organ damage, is not well studied. We aimed to investigate the relationship between IL-18 and LVH in apparently healthy subjects free of clinically significant atherosclerotic disease. Subjects and Methods: We enrolled 198 subjects (102 women and 96 men) between May 2006 and March 2007, who were free of cardiovascular or immune diseases, but were suspected to have hypertension. Twenty-four-hour ambulatory blood pressure monitoring and two-dimensional echocardiography were performed. Lipid profiles, high-sensitivity CRP (hs-CRP), IL-18, and whole blood cell counts were measured for all subjects. Results: White blood cell count, hs-CRP, left ventricular mass, left ventricular mass index (LVMI), and IL-18 were higher in the hypertensive group than in the normotensive group (p=0.045, p=0.004, p<0.0001, p=0.001, and p=0.017 respectively). Twenty-four hour day and night systolic and diastolic blood pressure averages were positively correlated with IL-18 level in the entire study population. In multivariate regression analysis, left ventricular mass index and hs-CRP level were independently associated with IL-18 level in both the hypertensive group and the entire study population (${\beta}=0.154$, ${\beta}=0.149$ p=0.033, p=0.040 and ${\beta}=0.151$, ${\beta}=0.155$ p=0.036, p=0.032 respectively) Conclusion: We found that IL-18 level independently predicted LVMI in both the general population and in newly diagnosed hypertensive patients.

Keywords

References

  1. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001;19:857-61. https://doi.org/10.1097/00004872-200105000-00004
  2. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005;19:149-54. https://doi.org/10.1038/sj.jhh.1001785
  3. Borekci A, Gur M, Turkoglu C, et al. Neutrophil to lymphocyte ratio predicts left ventricular remodeling in patients with ST elevation myocardial infarction after primary percutaneous coronary intervention. Korean Circ J 2016;46:15-22. https://doi.org/10.4070/kcj.2016.46.1.15
  4. Dehghani MR, Rezaei Y, Fakour S, Arjmand N. White blood cell count to mean platelet volume ratio is a prognostic factor in patients with non-ST elevation acute coronary syndrome with or without metabolic syndrome. Korean Circ J 2016;46:229-38. https://doi.org/10.4070/kcj.2016.46.2.229
  5. Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006;188:450-4. https://doi.org/10.1016/j.atherosclerosis.2005.11.013
  6. Aso Y, Okumura K, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 2003;26:2622-7. https://doi.org/10.2337/diacare.26.9.2622
  7. Colston JT, Boylston WH, Feldman MD, et al. Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload. Biochem Biophys Res Commun 2007;354:552-8. https://doi.org/10.1016/j.bbrc.2007.01.030
  8. Woldbaek PR, Sande JB, Stromme TA, et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol 2005;289:H708-14. https://doi.org/10.1152/ajpheart.01179.2004
  9. Vilarrasa N, Vendrell J, Maravall J, et al. IL-18: relationship with anthropometry, body composition parameters, leptin and arterial hypertension. Horm Metab Res 2006;38:507-12. https://doi.org/10.1055/s-2006-949122
  10. Thorand B, Kolb H, Baumert J, et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/ KORA Augsburg study, 1984-2002. Diabetes 2005;54:2932-8. https://doi.org/10.2337/diabetes.54.10.2932
  11. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2015;28:1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
  12. Blankenberg S, Luc G, Ducimetiere P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003;108:2453-9. https://doi.org/10.1161/01.CIR.0000099509.76044.A2
  13. Pickering TG, White WB. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008;2:119-24. https://doi.org/10.1016/j.jash.2008.04.002
  14. Gaborieau V, Delarche N, Gosse P. Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: correlation with target organ damage. J Hypertens 2008;26:1919-27. https://doi.org/10.1097/HJH.0b013e32830c4368
  15. Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens 2008;26:1290-9. https://doi.org/10.1097/HJH.0b013e3282f97854
  16. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007;370:1219-29. https://doi.org/10.1016/S0140-6736(07)61538-4
  17. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008;51:55-61. https://doi.org/10.1161/HYPERTENSIONAHA.107.100727
  18. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens 2009;27:2121-58. https://doi.org/10.1097/HJH.0b013e328333146d
  19. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6. https://doi.org/10.1001/jama.292.19.2350
  20. Blacher J, Evans A, Arveiler D, et al. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME study. J Hum Hypertens 2010;24:19-26. https://doi.org/10.1038/jhh.2009.34
  21. Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 2009;6:192-9.
  22. Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res 2006;71:216-25. https://doi.org/10.1016/j.cardiores.2006.02.033
  23. Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I, Natarajan R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 2005;96:1064-71. https://doi.org/10.1161/01.RES.0000168210.10358.f4
  24. Doi T, Sakoda T, Akagami T, et al. Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol 2008;295:H1279-H87. https://doi.org/10.1152/ajpheart.00148.2008
  25. Rumantir MS, Jennings GL, Lambert GW, Kaye DM, Seals DR, Esler MD. The 'adrenaline hypothesis' of hypertension revisited: evidence for adrenaline release from the heart of patients with essential hypertension. J Hypertens 2000;18:717-23. https://doi.org/10.1097/00004872-200018060-00009
  26. Chandrasekar B, Marelli-Berg FM, Tone M, Bysani S, Prabhu SD, Murray DR. Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun 2004;319:304-11. https://doi.org/10.1016/j.bbrc.2004.04.185
  27. Mistry P, Reid J, Pouliquen I, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin-18 mAb GSK1070806 in healthy and obese subjects. Int J Clin Pharmacol Ther 2014;52:867-79. https://doi.org/10.5414/CP202087
  28. Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 2006;31:109-16. https://doi.org/10.1007/BF03191127
  29. O'Brien LC, Mezzaroma E, Van Tassell BW, et al. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med 2014;20:221-9.
  30. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-57. https://doi.org/10.1084/jem.20011022

Cited by

  1. NLR-A Simple Indicator of Inflammation for the Diagnosis of Left Ventricular Hypertrophy in Patients with Hypertension vol.61, pp.2, 2020, https://doi.org/10.1536/ihj.19-138
  2. Changes in blood levels of IL1 family cytokines in patients with essential hypertension after having COVID-19 vol.2021, pp.2021, 2017, https://doi.org/10.24075/brsmu.2021.026
  3. Plasma S1P (Sphingosine-1-Phosphate) Links to Hypertension and Biomarkers of Inflammation and Cardiovascular Disease: Findings From a Translational Investigation vol.78, pp.1, 2017, https://doi.org/10.1161/hypertensionaha.120.17379